Genetics

DNA Script Appoints Don Kania as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as Independent Director

Research, Technology, Medical Devices, FDA, Genetics, Clinical Trials, Biotechnology, Hardware, Health, Science, SYNTAX, Enzyme, Research, Technology, Industry, Genomics, Partnership, EDS, CMR Surgical, View, Director, Leadership, Synthetic biology, Board on Science, Technology, and Economic Policy, Board, CEO, Organic acid, FEI Company, Script, Thermo Fisher Scientific, DNA, Management
Thursday, October 21, 2021 - 10:00am

DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.

Key Points: 
  • DNA Script, a leader in Enzymatic DNA Synthesis (EDS), today announced the appointment of Don Kania, Ph.D. as Chairman of the Board of Directors, Catherine Moukheibir as Audit Chair and Bonnie Anderson as independent new members of the Board.
  • The life sciences industry is in the process of revolutionizing our world, starting with healthcare and expanding into other markets.
  • Moukheibir brings over 30 years of leadership experience in finance, capital markets and life sciences to DNA Script.
  • DNA Script is at a pivotal point with the targeted commercial launch of our SYNTAX Platform, said Thomas Ybert, DNA Script co-founder and CEO.

MDxHealth Provides Q3-2021 Business Update

Bachelor of Arts, Diagnosis, University, Prognosis, Cancer, University of North Carolina School of the Arts, LabCorp, Genetics, Patient, Quest Diagnostics, Methylation, Physician, Don, Social media, Chapel Hill, Company, CEO, Growth, Nasdaq, Prostate cancer, Management, Medical imaging
Thursday, October 21, 2021 - 6:00am

From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company.

Key Points: 
  • From April 2010 to March 2016, Mr. Hardison was the President and Chief Executive Officer of Good Start Genetics, a molecular genetic testing and information company.
  • Michael K. McGarrity, CEO of MDxHealth commented: We are very excited to welcome Don Hardison to our board of directors.
  • Dons breadth of experience and reach into the U.S. and global diagnostic industry will serve MDxHealth well as we go forward.
  • MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Safety, RNA transfection, Duke–NUS Medical School, Takeda Pharmaceutical Company, Cystic Fibrosis Foundation, Director, LinkedIn, Vaccine, Cystic fibrosis, ARCT, Hepatitis B virus, Messenger RNA, Twitter, Janssen Pharmaceuticals, Private Securities Litigation Reform Act, RNA, SEC, Infection, Severe acute respiratory syndrome coronavirus 2, Annual report, Glycogen storage disease, Johnson & Johnson, Company, Patent, Risk, Financial compensation, Intention, OTC, COVID-19, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., Nasdaq, Fatty liver disease, NASH, MicroRNA, Employment, Therapy, CureVac, Liver, Gene editing, DNA
Thursday, October 21, 2021 - 1:00am

The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.

Key Points: 
  • The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individuals employment compensation and were granted as an inducement material to his or her acceptance of employment with the Company.
  • The options have an exercise price equal to $46.98 per share, the closing price of the Companys common stock as reported by Nasdaq on October 15, 2021.
  • Arcturus versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics.
  • Arcturus technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries).

23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021

Research, Securities Act of 1933, Genome, CA, Security (finance), U.S. Securities and Exchange Commission, Genetics, FDA, Degenerative disease, Terminology, SEC, Lijun International Pharmaceutical (Holding) Co. Ltd., Company, Webcast, Growth, Therapy, Publication, GLOBE, Securities Exchange Act of 1934, Pharmaceutical industry
Wednesday, October 20, 2021 - 11:30pm

SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter before the market opens on Wednesday, November 10, 2021.

Key Points: 
  • SUNNYVALE, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter before the market opens on Wednesday, November 10, 2021.
  • The Company will webcast a conference call at 4:30 p.m. Eastern Time to discuss the quarters financial results and report on business progress.
  • A webcast replay will be available at the same address for a limited time within 24 hours after the event.
  • 23andMe has pioneered direct access to genetic information as the only company with multiple FDA authorizations for genetic health risk reports.

Catalent, Inc. Announces First Quarter Fiscal Year 2022 Earnings Conference Webcast

Science, Other Science, Biotechnology, Other Manufacturing, Medical Supplies, Health, Genetics, Manufacturing, S&P, NYSE, Webcast, Industry, CTLT, Broadcasting
Wednesday, October 20, 2021 - 10:15pm

The Companys management will host a webcast to discuss the results at 8:15 a.m.

Key Points: 
  • The Companys management will host a webcast to discuss the results at 8:15 a.m.
  • Catalent invites all interested parties to listen to the webcast, which will be accessible through Catalents website at http://investor.catalent.com .
  • A supplemental slide presentation will also be available in the Investors section of Catalents website prior to the start of the webcast.
  • The webcast replay, along with the supplemental slides, will be available for 90 days in the Investors section at www.catalent.com .

Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company

Health, Medical Devices, Consumer, Clinical Trials, Men, Research, Science, Safety, Woman, MD, Biotechnology, Quality of life, Entrepreneurship, Hospital, Condom, Knowledge, Ethics, Founders Fund, NIH, Human, Patient, Birth, University of Utah School of Medicine, Acting, MBX, Vasectomy, Infertility, University, Clinical trial, Man, Public health, ADAM, IOS, Male, Health, Fertility, Female, Sexual dysfunction, Doctor of Philosophy, Jaffray Woodriff, Genetics, Financial services, Birth control
Wednesday, October 20, 2021 - 5:00pm

Contraline, Inc ., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing.

Key Points: 
  • Contraline, Inc ., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has closed $10.7 million in its Series A financing.
  • The financing round was led by MBX Capital, a venture capital firm that invests in early-stage healthcare and life sciences companies.
  • Contraline has received ethics approval from the Human Research Ethics Committee based in Melbourne, Australia to conduct the study.
  • Contraline, Inc. is a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective contraception.

Nutrafol Launches the First and Only Hair Serum Leveraging Patent-Pending Plant Exosome Technology

Genetics, Biotechnology, Hair, Man, Woman, Hormone, COVID-19, Seed, Multimedia, Industry, Exosome, Scalp, Physician, Environment, Science, Cosmetics
Wednesday, October 20, 2021 - 3:00pm

The new, revolutionary hair serum is the first scalp-care product that leverages the science of plant exosome technology to boost cellular renewal on the scalp for thicker-looking hair.

Key Points: 
  • The new, revolutionary hair serum is the first scalp-care product that leverages the science of plant exosome technology to boost cellular renewal on the scalp for thicker-looking hair.
  • Growth Activator is a lightweight, first-of-its-kind hair serum that unlocks the power of exosomes from inside the Ashwagandha plant, traditionally a clinically effective and scientifically proven stress adaptogen.
  • Nutrafol engineered a method for isolating exosomes from the seeds of the same Ashwagandha plant used in Nutrafol's Hair Growth Nutraceuticals.
  • The company's use of plant exosome technology marks a major milestone for Nutrafol, demonstrating the brand's ongoing commitment to drive hair science innovation forward.

DreaMed Launches its FDA-Cleared Diabetes Management Platform with a Leading U.S. Children's Hospital

Technology, Medical Devices, Hospitals, FDA, Genetics, Fitness & Nutrition, Clinical Trials, Biotechnology, Health, Data Management, Texas Children's Hospital, American Diabetes Association, Injection, Medtronic, Technology, Hospital, LTD, Diabetes, Glucose, Adviser, Yale New Haven Health System, FDA, CEO, More Than Just a Dream, Data analysis, Patient, University, Type 1 and type 2 sequence, The Company, Solution, Pediatrics, Pharmaceutical industry
Wednesday, October 20, 2021 - 2:22pm

DreaMed Diabetes AI LTD. ("DreaMed" or the "Company"), a developer of the Advisor Pro Al Clinical Decision Support platform for diabetes, announced today it deployed its DreaMeds Advisor Pro - a digital diabetes management platform in one of the top 10 metropolitan U.S. children's hospital1.

Key Points: 
  • DreaMed Diabetes AI LTD. ("DreaMed" or the "Company"), a developer of the Advisor Pro Al Clinical Decision Support platform for diabetes, announced today it deployed its DreaMeds Advisor Pro - a digital diabetes management platform in one of the top 10 metropolitan U.S. children's hospital1.
  • Advisor Pro by DreaMed is an Al Clinical Decision Support System for diabetes, providing remote insulin management with data analysis and therapy management tools.
  • The solution was deployed at the hospital together with existing diabetes management protocols so patients can receive a personalized, precise, and effective diabetes treatment.
  • Since then, DreaMed Diabetes has been vigorously working on the DreaMed Advisor portfolio, decision support tools in diabetes management.

CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease

Biotechnology, Pharmaceutical, Genetics, Health, ERT, Clinical trial, Spiroplasma mirum, Doctor of Philosophy, IND, CDE, Genetic distance, Degenerative disease, Cell, Investigational New Drug, Haemophilia, WuXi Biologics, Gaucher, Splenomegaly, Enzyme replacement therapy, University, Disease, Anemia, GBA, GBM, Research, Mutation, Bone pain, III, MPS II, Glioblastoma, Quality of life, CEO, Disorder, University of Massachusetts Medical School, LSS, Patient, Thrombocytopenia, LSD, Glycogen storage disease, Partnership, MPS, NMPA, Gaucher's disease, Frost & Sullivan, Hunter syndrome, Lists of diseases, University of Massachusetts, Hepatomegaly, Pharmaceutical industry, Fine chemical
Wednesday, October 20, 2021 - 1:00pm

CAN103 is an enzyme replacement therapy (ERT) being developed by CANbridge as part of its rare disease partnership with WuXi Biologics (2269.HK) for the long-term treatment of adults and children with Gaucher disease, Types I and III.

Key Points: 
  • CAN103 is an enzyme replacement therapy (ERT) being developed by CANbridge as part of its rare disease partnership with WuXi Biologics (2269.HK) for the long-term treatment of adults and children with Gaucher disease, Types I and III.
  • Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc. We are working diligently to commence our clinical trial program in CAN103, one of the candidates from our partnership with WuXi Biologics.
  • Despite the fact that Gaucher disease treatments have been available in China for decades, most patients do not have access, underscoring the need for China-based treatments and solutions.
  • CANbridge Pharmaceuticals Inc. is a China-based global rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies.

Parse Biosciences Unveils 1,000,000 Cell scRNA-seq Kit

Oncology, Health, Genetics, General Health, Research, Science, Biotechnology, Immune system, American Society of Human Genetics, Cell, Technology, Kidney, CTO, Genetics, Solution, RNA, Research, Laboratory, CEO, Health, ASHG, Human genetics, Society, Vaccine, Mobile phone, Fine chemical, Video game console
Wednesday, October 20, 2021 - 1:00pm

Our one million cell solution represents the next evolution for single-cell sequencing, said Alex Rosenberg, PhD., CEO and co-founder of Parse Biosciences.

Key Points: 
  • Our one million cell solution represents the next evolution for single-cell sequencing, said Alex Rosenberg, PhD., CEO and co-founder of Parse Biosciences.
  • Parses newest product addition is based on the same split-pool combinatorial barcoding technology as its 100,000 cell kit previously launched in February 2021, now called the Evercode Whole Transcriptome Kit.
  • Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research.
  • At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease.